Triple Therapy in Type 2 Diabetes: Insulin Glargine or Rosiglitazone Added to Combination Therapy of Sulfonylurea Plus Metformin in Insulin-Naive Patients

Drs. Hamid and Simmons (1) comment on two positive aspects that favor the use of insulin glargine over rosiglitazone as add-on therapy in type 2 diabetic patients who are inadequately controlled on sulfonylurea plus metformin therapy. The first is whether the beneficial lipid effects found with insulin glargine versus rosiglitazone translate to better clinical outcomes. The second is in regard to the assessment of the cost profile associated with glargine. The neutral effect on LDL levels …